Latest Research in Cancer Immunotherapy and Biomarkers
112 research papers · 2026 median publication year
Top Research Topics in Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers — 12 papers
- Renal cell carcinoma treatment — 11 papers
- Bladder and Urothelial Cancer Treatments — 7 papers
- Endometrial and Cervical Cancer Treatments — 7 papers
- PARP inhibition in cancer therapy — 6 papers
- Ovarian cancer diagnosis and treatment — 6 papers
- Gastric Cancer Management and Outcomes — 5 papers
- Cancer Genomics and Diagnostics — 5 papers
- Esophageal Cancer Research and Treatment — 4 papers
- Lung Cancer Research Studies — 4 papers
Highest-Cited Papers
- Combination of Immune Checkpoint Inhibitors With Vascular Endothelial Growth Factor–Targeted Agents in Advanced Gastric and Gastroesophageal Adenocarcinoma
- Ex Vivo Microtumor Testing to Predict Chemotherapy Responses in Patients with Bladder Cancer
- The clinical and phenotypic spectrum of PTEN hamartoma tumor syndrome: a retrospective cohort study
- Safety of eribulin: A real-world study based on a pharmacovigilance database
- Comparative Gene Expression Analysis of Epithelioid Pleural and Peritoneal Mesothelioma
- Early tumor shrinkage during first-line immune checkpoint inhibitor–based chemotherapy is associated with progression-free survival in measurable unresectable gastric cancer
- Acquired von Willebrand Syndrome Associated With Wilms Tumour
- Reappraisal of Cisplatin vs Carboplatin Treatment for Solid Tumors
- Effectiveness of first-line niraparib maintenance in Korean patients with advanced ovarian cancer: a multicenter retrospective cohort study
- Impact of post‐chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children’s Oncology Group AREN0532, AREN0533, and AREN03B2 studies
- Correlation of bevacizumab relative dose intensity with first-line treatment outcomes in advanced epithelial ovarian cancer
- Landscape of approaches for streamlining pre-analytical and early analytical variables for solid tumor next-generation sequencing: A Genomics Organization for Academic Laboratories consortium report
- Immunohistochemical stratification of bladder small cell carcinoma reveals two major phenotypes with distinct therapeutic biomarker profiles
- Factors associated with early death among children and adolescents with cancer in Brazil: a nationwide registry-based study
- Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201
- Immune checkpoint inhibitors in advanced upper-tract urothelial carcinoma: a multicenter study
- IMMU‐NO versus yes: Applicability of immune checkpoint inhibitors in gynecologic cancers
- Immune Checkpoint Inhibitor-related Adverse Events in Publicly Accessible United States Malpractice Records: A Systematic Legal Database Review, 2015 to 2026
- A new paradigm for treating recurrent platinum-resistant ovarian cancer: synergistic mechanisms, clinical evidence, and future directions of immune checkpoint inhibitors combined with PARP inhibitors
- Comparative Evaluation of the Effectiveness of Nivolumab Versus Axitinib in the Second-Line Treatment of Patients with Metastatic Renal Cell Carcinoma: A Two-Center Experience